SANTA BARBARA, Calif., Aug. 12, 2021 /PRNewswire/ — Bexson Biomedical today announced the launch of its R&D initiative to develop novel subcutaneous formulations of several different psychedelics, empathogen and other psychoactive compounds. The effort applies the company’s existing subcutaneous formulation technology to several psychoactive drug scaffolds for the treatment of mental health…


Previous articleBeckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs
Next articleIn Awe: Psychedelic Assisted Psychotherapy and the Mystical Experience